Legend Biotech (NASDAQ: LEGN) CEO disposes shares to cover RSU tax

Rhea-AI Filing Summary

Legend Biotech Corp Chief Executive Officer Ying Huang reported a disposition of ordinary shares tied to equity compensation taxes. On June 25, 2026, 5,566 ordinary shares were sold at a weighted average price of $14.78 per share, based on converted ADS prices.

According to the disclosure, these shares were sold to satisfy withholding tax obligations upon the vesting of restricted share units, making this a compensation-related, non-discretionary event rather than a typical open-market sale. Following the transaction, Huang directly holds 241,872 ordinary shares of Legend Biotech.

Insider Trade Summary

Net Seller: 5,566 shares ($82,265)

Net Sell 1 txn

Insider Huang Ying

Role Chief Executive Officer

Sold 5,566 shs ($82K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	5,566	$14.78	$82K

Holdings After Transaction: Ordinary Shares — 241,872 shares (Direct, null)

Footnotes (1)

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer. Represents shares sold to satisfy withholding tax obligations upon the vesting of restricted share units. The price reported in Column 4 is a weighted average price and represents the converted sales price of the ADSs of $29.56. The prices sold ranged from $28.13 to $29.98 per ADS (which is equivalent to $14.065 to $14.99 per ordinary share). The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares disposed: 5,566 ordinary shares Weighted average price per ordinary share: $14.78 per share Weighted average ADS price: $29.56 per ADS +2 more

5 metrics

Shares disposed 5,566 ordinary shares Tax-related disposition on June 25, 2026

Weighted average price per ordinary share $14.78 per share Converted from ADS weighted average price

Weighted average ADS price $29.56 per ADS Underlying ADS transaction for the share sale

ADS sale price range $28.13–$29.98 per ADS Equivalent to $14.065–$14.99 per ordinary share

Shares held after transaction 241,872 ordinary shares Direct holdings by CEO Ying Huang post-transaction

Key Terms

American Depositary Shares, restricted share units, weighted average price

3 terms

American Depositary Shares financial

"The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs")."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

restricted share units financial

"Represents shares sold to satisfy withholding tax obligations upon the vesting of restricted share units."

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

weighted average price financial

"The price reported in Column 4 is a weighted average price and represents the converted sales price of the ADSs of $29.56."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 09:53 PM Accepted by SEC EDGAR 06/29/2026 - 09:53 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Huang Ying

(Last) (First) (Middle)

C/O LEGEND BIOTECH CORP

2101 COTTONTAIL LANE

(Street)

SOMERSET NEW JERSEY 08873

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/25/2026		S(2)		5,566	D	$14.78(3)	241,872	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

2. Represents shares sold to satisfy withholding tax obligations upon the vesting of restricted share units.

3. The price reported in Column 4 is a weighted average price and represents the converted sales price of the ADSs of $29.56. The prices sold ranged from $28.13 to $29.98 per ADS (which is equivalent to $14.065 to $14.99 per ordinary share). The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

	/s/ James Pepin, Attorney-in-Fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Legend Biotech (LEGN) report for CEO Ying Huang?

Legend Biotech reported that CEO Ying Huang disposed of 5,566 ordinary shares. The shares were sold to cover withholding tax obligations arising from the vesting of restricted share units, rather than as a discretionary open-market sale for investment purposes.

At what price were the Legend Biotech (LEGN) shares related to this Form 4 sold?

The reported weighted average price was $14.78 per ordinary share. This reflects a converted ADS sales price of $29.56, with ADS sale prices ranging from $28.13 to $29.98, equivalent to $14.065 to $14.99 per ordinary share.

How many Legend Biotech (LEGN) shares does CEO Ying Huang hold after this transaction?

After the tax-related share disposition, CEO Ying Huang directly holds 241,872 ordinary shares. This post-transaction balance shows that the 5,566 shares involved represent a relatively small portion of his overall reported share ownership in Legend Biotech.

Was the Legend Biotech (LEGN) CEO’s Form 4 transaction a routine tax withholding event?

Yes. The filing states the shares were sold to satisfy withholding tax obligations upon vesting of restricted share units. Such transactions are typically driven by tax requirements associated with equity compensation, rather than a change in the insider’s investment view.

How are Legend Biotech (LEGN) ordinary shares and ADSs related in this Form 4?

The Form 4 notes that Legend Biotech’s ordinary shares may be represented by American Depositary Shares. Each ADS represents two ordinary shares, and the reported per-share prices reflect ADS trades converted into equivalent ordinary share values.

Does the Legend Biotech (LEGN) Form 4 indicate any derivative or option exercises?

No derivative or option exercises are indicated in the provided data. The transaction involves only ordinary shares sold in connection with tax withholding on vested restricted share units, with no remaining derivative positions listed in the derivative summary section.